Circadian control of tumor immunosuppression affects efficacy of immune checkpoint blockade
Comprehensive Overview
This study, published in Nature Immunology (2024), investigated whether the body's internal 24-hour biological clock, known as the circadian clock, influences how well the immune system can recognize and attack tumors, and whether this rhythm could be exploited to improve a class of cancer drugs called immune checkpoint inhibitors, which work by releasing natural brakes on the immune system so it can attack cancer cells. Researchers used genetically engineered mice that develop colorectal cancer, some of which also had a disabled circadian clock gene, and analyzed the immune cells present in and around their tumors in detail. They found that disrupting the circadian clock increased the abundance of immunosuppressive immune cells that shield tumors from attack, while reducing the number of cytotoxic T cells, the immune system's primary tumor-killing cells. Importantly, these immunosuppressive cells were not present at constant levels throughout the day, but instead rose and fell in a predictable daily rhythm, peaking during the animals' active, waking period. Researchers then tested whether timing a checkpoint inhibitor drug to coincide with this peak, rather than administering it at a random time, could improve how effectively the treatment shrank tumors.
Outcomes and Implications
The most notable finding was that immunosuppressive myeloid cells and their associated protein, PD-L1, which tumors use to evade immune attack, followed a clear daily rhythm, peaking during the active phase and dropping during the rest phase, and that checkpoint therapy worked significantly better when timed to match this peak. In mice with colorectal cancer, treatment given during the active-phase peak led to smaller tumors, smaller precancerous growths, and a notably higher rate of complete tumor disappearance compared to treatment given during the rest phase, which showed little benefit at all. This same time-of-day advantage held up across several additional cancer types tested in separate mouse models, including colorectal cancer, lung cancer, and melanoma, suggesting the pattern is not unique to one tumor type. At the cellular level, disrupting the circadian clock in the intestinal lining triggered a cascade of inflammatory signals that recruited immune-suppressing cells and impaired the tumor-killing T cells needed for an effective immune response. Researchers also confirmed these same immunosuppressive, PD-L1-marked cells are notably abundant in tumor samples from human colorectal cancer patients, strengthening the case that the findings are relevant beyond mice. This matters because many cancer patients do not respond well to checkpoint inhibitor drugs despite their promise, and adjusting when these drugs are administered could be a simple, low-cost way to improve outcomes. The authors conclude these findings support clinical trials testing whether time-of-day dosing can meaningfully improve immunotherapy effectiveness in humans.